These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35616802)

  • 1. Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry.
    Abduljaleel Z; Shahzad N; Aziz SA; Malik SM
    Mol Divers; 2023 Apr; 27(2):695-708. PubMed ID: 35616802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
    Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
    Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
    Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
    Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
    Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
    Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 9. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
    Jiang M; Zhang G; Liu H; Ding P; Liu Y; Tian Y; Wang Y; Wang A
    Front Immunol; 2021; 12():707977. PubMed ID: 34621266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo design and Rosetta-based assessment of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike receptor binding domain (RBD).
    Boorla VS; Chowdhury R; Ramasubramanian R; Ameglio B; Frick R; Gray JJ; Maranas CD
    Proteins; 2023 Feb; 91(2):196-208. PubMed ID: 36111441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
    Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
    Gattinger P; Niespodziana K; Stiasny K; Sahanic S; Tulaeva I; Borochova K; Dorofeeva Y; Schlederer T; Sonnweber T; Hofer G; Kiss R; Kratzer B; Trapin D; Tauber PA; Rottal A; Körmöczi U; Feichter M; Weber M; Focke-Tejkl M; Löffler-Ragg J; Mühl B; Kropfmüller A; Keller W; Stolz F; Henning R; Tancevski I; Puchhammer-Stöckl E; Pickl WF; Valenta R
    Allergy; 2022 Jan; 77(1):230-242. PubMed ID: 34453317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.
    Passariello M; Gentile C; Ferrucci V; Sasso E; Vetrei C; Fusco G; Viscardi M; Brandi S; Cerino P; Zambrano N; Zollo M; De Lorenzo C
    Sci Rep; 2021 May; 11(1):11046. PubMed ID: 34040046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
    He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
    J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.